|
Hepatitis Interest1 #703973
| Tags: hepatitis C virus (HCV), hepatitis delta virus, HDV |
+Citations (6) - CitationsAdd new citationList by: CiterankMapLink[1] Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study
Author: Charlotte Lanièce Delaunay, Marina B. Klein, Arnaud Godin, Joseph Cox, Nadine Kronfli, Bertrand Lebouché, Carla Doyle, Mathieu Maheu-Giroux Publication date: 17 April 2023 Publication info: International Journal of Drug Policy, Volume 116, 2023, 104026, ISSN 0955-3959 Cited by: David Price 6:36 PM 11 December 2023 GMT Citerank: (5) 679844Mathieu Maheu-GirouxCanada Research Chair (Tier 2) in Population Health Modeling and Associate Professor, McGill University.10019D3ABAB, 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0, 704045Covid-19859FDEF6, 715328Nonpharmaceutical Interventions (NPIs)859FDEF6, 715390Mortality859FDEF6 URL: DOI: https://doi.org/10.1016/j.drugpo.2023.104026
| Excerpt / Summary [International Journal of Drug Policy, 17 April 2023]
Background: In Montreal (Canada), high hepatitis C virus (HCV) seroincidence (21 per 100 person-years in 2017) persists among people who have injected drugs (PWID) despite relatively high testing rates and coverage of needle and syringe programs (NSP) and opioid agonist therapy (OAT). We assessed the potential of interventions to achieve HCV elimination (80% incidence reduction and 65% reduction in HCV-related mortality between 2015 and 2030) in the context of COVID-19 disruptions among all PWID and PWID living with HIV.
Methods: Using a dynamic model of HCV-HIV co-transmission, we simulated increases in NSP (from 82% to 95%) and OAT (from 33% to 40%) coverage, HCV testing (every 6 months), or treatment rate (100 per 100 person-years) starting in 2022 among all PWID and PWID living with HIV. We also modeled treatment scale-up among active PWID only (i.e., people who report injecting in the past six months). We reduced intervention levels in 2020–2021 due to COVID-19-related disruptions. Outcomes included HCV incidence, prevalence, and mortality, and proportions of averted chronic HCV infections and deaths.
Results: COVID-19-related disruptions could have caused temporary rebounds in HCV transmission. Further increasing NSP/OAT or HCV testing had little impact on incidence. Scaling-up treatment among all PWID achieved incidence and mortality targets among all PWID and PWID living with HIV. Focusing treatment on active PWID could achieve elimination, yet fewer projected deaths were averted (36% versus 48%).
Conclusions: HCV treatment scale-up among all PWID will be required to eliminate HCV in high-incidence and prevalence settings. Achieving elimination by 2030 will entail concerted efforts to restore and enhance pre-pandemic levels of HCV prevention and care. |
Link[2] Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
Author: The Polaris Observatory Collaborators Publication date: 23 July 2023 Publication info: The Lancet Gastroenterology and Hepatology, VOLUME 8, ISSUE 10, P879-907, OCTOBER 2023 Cited by: David Price 12:28 PM 14 December 2023 GMT Citerank: (2) 679856Naveed Zafar JanjuaDr. Naveed Zafar Janjua is an epidemiologist and senior scientist at the BC Centre for Disease Control and Clinical Associate Professor at School of Population and Public Health, University of British Columbia. Dr. Janjua is a Medical Doctor (MBBS) with a Masters of Science (MSc) degree in Epidemiology & Biostatistics and Doctorate in Public Health (DrPH). 10019D3ABAB, 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0 URL: DOI: https://doi.org/10.1016/S2468-1253(23)00197-8
| Excerpt / Summary [The Lancet Gastroenterology and Hepatology, October 2023]
Background: The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infection as a public health threat by 2030; existing therapies and prophylaxis measures make such elimination feasible, even in the absence of a virological cure. We aimed to estimate the national, regional, and global prevalence of HBV in the general population and among children aged 5 years and younger, as well as the rates of diagnosis, treatment, prophylaxis, and the future burden globally.
Methods: In this modelling study, we used a Delphi process with data from literature reviews and interviews with country experts to quantify the prevalence, diagnosis, treatment, and prevention measures for HBV infection. The PRoGReSs Model, a dynamic Markov model, was used to estimate the country, regional, and global prevalence of HBV infection in 2022, and the effects of treatment and prevention on disease burden. The future incidence of morbidity and mortality in the absence of additional interventions was also estimated at the global level.
Findings: We developed models for 170 countries which resulted in an estimated global prevalence of HBV infection in 2022 of 3·2% (95% uncertainty interval 2·7–4·0), corresponding to 257·5 million (216·6–316·4) individuals positive for HBsAg. Of these individuals, 36·0 million were diagnosed, and only 6·8 million of the estimated 83·3 million eligible for treatment were on treatment. The prevalence among children aged 5 years or younger was estimated to be 0·7% (0·6–1·0), corresponding to 5·6 million (4·5–7·8) children with HBV infection. Based on the most recent data, 85% of infants received three-dose HBV vaccination before 1 year of age, 46% had received a timely birth dose of vaccine, and 14% received hepatitis B immunoglobulin along with the full vaccination regimen. 3% of mothers with a high HBV viral load received antiviral treatment to reduce mother-to-child transmission.
Interpretation: As 2030 approaches, the elimination targets remain out of reach for many countries under the current frameworks. Although prevention measures have had the most success, there is a need to increase these efforts and to increase diagnosis and treatment to work towards the elimination goals. |
Link[3] Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study
Author: Gaelen Snell, Alison D Marshall, Jennifer van Gennip, Matthew Bonn, Janet Butler-McPhee, Curtis L Cooper, Nadine Kronfli, Sarah Williams, Julie Bruneau, Jordan J Feld, Naveed Z Janjua, Marina Klein, Nance Cunningham, Jason Grebely, Sofia R Bartlett Publication date: 1 July 2023 Publication info: Canadian Liver Journal, Volume 6 Issue 2, July 2023, pp. pp. 190-200 Cited by: David Price 2:03 PM 14 December 2023 GMT Citerank: (2) 679856Naveed Zafar JanjuaDr. Naveed Zafar Janjua is an epidemiologist and senior scientist at the BC Centre for Disease Control and Clinical Associate Professor at School of Population and Public Health, University of British Columbia. Dr. Janjua is a Medical Doctor (MBBS) with a Masters of Science (MSc) degree in Epidemiology & Biostatistics and Doctorate in Public Health (DrPH). 10019D3ABAB, 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0 URL: DOI: https://doi.org/10.3138/canlivj-2022-0040
| Excerpt / Summary [Canadian Liver Journal, July 2023]
Background: Direct-acting antiviral (DAA) therapies have simplified HCV treatment, and publicly funded Canadian drug plans have eliminated disease-stage restrictions for reimbursement of DAA therapies. However other policies which complicate, delay, or prevent treatment initiation still persist. We aim to describe these plans’ existing reimbursement criteria and appraise whether they hinder treatment access.
Methods: We reviewed DAA reimbursement policies of 16 publicly funded drug plans published online and provided by contacts with in-depth knowledge of prescribing criteria. Data were collected from May to July 2022. Primary outcomes were: (1) if plans have arranged to accept point-of-care HCV RNA testing for diagnosis; testing requirements for (2) HCV genotype, (3) fibrosis stage, and (4) chronic infection; (5) time taken and method used to approve reimbursement requests; (6) providers eligible to prescribe DAAs; and (7) restrictions on re-treatment.
Results: Fifteen (94%) plans have at least one policy in place which limits simplified HCV treatment. Many plans continue to require results of genotype or fibrosis staging, limit eligible prescribers, and take longer than 1 day to approve coverage requests. One plan discourages treatment for re-infection.
Conclusion: Reimbursement criteria set by publicly funded Canadian drug plans continue to limit timely, equitable access to HCV treatment. Eliminating clinically irrelevant pre-authorization testing, expanding eligible prescribers, expediting claims processing, and broadening coverage of treatment for reinfection will improve access to DAAs. The federal government could further enhance efforts by introducing a federal HCV elimination strategy or federal high-cost drug PharmaCare program. |
Link[4] Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, Canada
Author: Dahn Jeong, Stanley Wong, Mohammad Ehsanul Karim, Amee R. Manges, Jean Damascene Makuza, Sofia R. Bartlett, Héctor Alexander Velásquez García, Daryl Luster, Prince Asumadu Adu, Mawuena Binka, Amanda Yu, Mel Krajden, Naveed Zafar Janjua Publication date: 29 December 2023 Publication info: The Lancet Regional Health - Americas, Volume 29, 2024, 100658, ISSN 2667-193X Cited by: David Price 0:14 AM 12 January 2024 GMT Citerank: (2) 679856Naveed Zafar JanjuaDr. Naveed Zafar Janjua is an epidemiologist and senior scientist at the BC Centre for Disease Control and Clinical Associate Professor at School of Population and Public Health, University of British Columbia. Dr. Janjua is a Medical Doctor (MBBS) with a Masters of Science (MSc) degree in Epidemiology & Biostatistics and Doctorate in Public Health (DrPH). 10019D3ABAB, 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0 URL: DOI: https://doi.org/10.1016/j.lana.2023.100658
| Excerpt / Summary [The Lancet Regional Health - Americas, 29 December 2023]
Background: HCV infection is associated with mortality due to extrahepatic manifestations (EHM). Sustained virologic response (SVR) following direct-acting antiviral (DAA) therapy has been linked to decreased all-cause and liver-related mortality. However, evidence regarding the impact of DAA on EHM-related deaths is lacking. This study aimed to assess the impact of DAA and SVR on EHM-related mortality.
Methods: The British Columbia Hepatitis Testers Cohort comprises ∼1.7 million people tested for HCV between 1990 and 2015 and is linked with administrative health data. Among individuals diagnosed with HCV by 12/31/2020, those who received at least one DAA treatment were matched to those who never received treatment by the year of their first HCV RNA positive date. We compared three groups: treated & SVR, treated & no-SVR, and untreated; and generated EHM mortality rates and incidence curves. To account for differences in baseline characteristics, we used inverse probability of treatment weights (IPTW). IPTW-weighted multivariable cause-specific Cox regression models were adjusted for competing risk and confounders.
Findings: Study population included 12,815 treated (12,287 SVR, 528 no-SVR) and 12,815 untreated individuals (median follow-up 3.4 years, IQR 2.9). The untreated group had the highest EHM mortality rate (30.9 per 1000 person-years [PY], 95% CI 29.2–32.8), followed by the treated & no-SVR group (21.2 per 1000 PY, 95% CI 14.9–30.1), while the treated & SVR group had the lowest EHM mortality rate (7.9 per 1000 PY, 95% CI 7.1–8.7). In the multivariable model, EHM mortality in the treated & SVR group was significantly decreased (adjusted cause-specific hazard ratio [acsHR] 0.20, 95% CI 0.18–0.23). The treated & SVR group had significant reductions in mortality related to each of the EHMs (78–84%).
Interpretation: Treatment of HCV with DAA was associated with significant reductions in EHM-related mortality. These findings emphasize the critical importance of timely diagnosis and treatment of HCV to prevent deaths associated with EHM, and have important implications for clinical practice and public health. |
Link[5] Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories
Author: The Polaris Observatory Collaborators Publication date: 26 November 2023 Publication info: Journal of Hepatology, Volume 80, Issue 2, P232-242, FEBRUARY 2024 Cited by: David Price 8:48 PM 4 March 2024 GMT Citerank: (2) 679856Naveed Zafar JanjuaDr. Naveed Zafar Janjua is an epidemiologist and senior scientist at the BC Centre for Disease Control and Clinical Associate Professor at School of Population and Public Health, University of British Columbia. Dr. Janjua is a Medical Doctor (MBBS) with a Masters of Science (MSc) degree in Epidemiology & Biostatistics and Doctorate in Public Health (DrPH). 10019D3ABAB, 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0 URL: DOI: https://doi.org/10.1016/j.jhep.2023.10.043
| Excerpt / Summary [Journal of Hepatology, 26 November 2023]
Background & Aims: Hepatitis delta virus (HDV) is a satellite RNA virus that requires the hepatitis B virus (HBV) for assembly and propagation. Individuals infected with HDV progress to advanced liver disease faster than HBV-monoinfected individuals. Recent studies have estimated the global prevalence of anti-HDV antibodies among the HBV-infected population to be 5-15%. This study aimed to better understand HDV prevalence at the population level in 25 countries/territories.
Methods: We conducted a literature review to determine the prevalence of anti-HDV and HDV RNA in hepatitis B surface antigen (HBsAg)-positive individuals in 25 countries/territories. Virtual meetings were held with experts from each setting to discuss the findings and collect unpublished data. Data were weighted for patient segments and regional heterogeneity to estimate the prevalence in the HBV-infected population. The findings were then combined with The Polaris Observatory HBV data to estimate the anti-HDV and HDV RNA prevalence in each country/territory at the population level.
Results: After adjusting for geographical distribution, disease stage and special populations, the anti-HDV prevalence among the HBsAg+ population changed from the literature estimate in 19 countries. The highest anti-HDV prevalence was 60.1% in Mongolia. Once adjusted for the size of the HBsAg+ population and HDV RNA positivity rate, China had the highest absolute number of HDV RNA+ cases.
Conclusions: We found substantially lower HDV prevalence than previously reported, as prior meta-analyses primarily focused on studies conducted in groups/regions that have a higher probability of HBV infection: tertiary care centers, specific risk groups or geographical regions. There is large uncertainty in HDV prevalence estimates. The implementation of reflex testing would improve estimates, while also allowing earlier linkage to care for HDV RNA+ individuals. The logistical and economic burden of reflex testing on the health system would be limited, as only HBsAg+ cases would be screened.
Impact and implications: There is a great deal of uncertainty surrounding the prevalence of hepatitis delta virus among people living with hepatitis B virus at the population level. In this study, we aimed to better understand the burden in 25 countries and territories, to refine techniques that can be used in future analyses. We found a lower prevalence in the majority of places studied than had been previously reported. These data can help inform policy makers on the need to screen people living with hepatitis B virus to find those coinfected with hepatitis delta virus and at high risk of progression, while also highlighting the pitfalls that other researchers have often fallen into. |
Link[6] Bridging Hepatitis C Care Gaps: A Modeling Approach for Achieving the WHO’s Targets in Ontario, Canada
Author: Yeva Sahakyan, Aysegul Erman, William W. L. Wong, Christina Greenaway, Naveed Janjua, Jeffrey C. Kwong, Beate Sander Publication date: 31 July 2024 Publication info: Viruses 2024, 16(8), 1224; 31 July 2024 Cited by: David Price 3:54 PM 9 December 2024 GMT Citerank: (3) 679757Beate SanderCanada Research Chair in Economics of Infectious Diseases and Director, Health Modeling & Health Economics and Population Health Economics Research at THETA (Toronto Health Economics and Technology Assessment Collaborative).10019D3ABAB, 679856Naveed Zafar JanjuaDr. Naveed Zafar Janjua is an epidemiologist and senior scientist at the BC Centre for Disease Control and Clinical Associate Professor at School of Population and Public Health, University of British Columbia. Dr. Janjua is a Medical Doctor (MBBS) with a Masters of Science (MSc) degree in Epidemiology & Biostatistics and Doctorate in Public Health (DrPH). 10019D3ABAB, 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0 URL: DOI: https://doi.org/10.3390/v16081224
| Excerpt / Summary [Viruses, 31 July 2024]
Background: The World Health Organization (WHO) has set hepatitis C (HCV) elimination targets for 2030. Understanding existing gaps in the “HCV care-cascade” is essential for meeting these targets. We aimed to identify the level of service scale-up needed along the “HCV care-cascade” to achieve the WHO’s HCV elimination targets in Ontario, Canada.
]Methods: By employing a decision analytic model, we projected the quality-adjusted life years (QALYs) and healthcare costs for individuals with HCV in Ontario. We increased RNA testing and treatment rates to 98%, followed by increasing antibody testing uptake until we achieved the WHO’s mortality target (i.e., a 65% reduction in liver-related mortality by 2030 vs. 2015).
Results: Without scaling up by 2030, the expected QALYs and costs per person were 9.156 and CAD 48,996, respectively. Improved RNA testing and treatment rates reduced liver-related deaths to 3.3/100,000, a 57% reduction from 2015. Further doubling the antibody testing rates can achieve the WHO’s mortality target in 2035, but not in 2030. Compared to the status quo, such program would be cost-effective considering a 50,000 CAD/QALY gained threshold if annual implementation costs stayed under 2.3 M CAD/100,000 people.
Conclusions: Doubling the antibody testing rates, along with increased RNA testing and treatment rates, showed promise in meeting the WHO’s goals by 2035. |
|
|